BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gong J, Pan K, Fakih M, Pal S, Salgia R. Value-based genomics. Oncotarget 2018;9:15792-815. [PMID: 29644010 DOI: 10.18632/oncotarget.24353] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 6.8] [Reference Citation Analysis]
Number Citing Articles
1 Noskova H, Kyr M, Pal K, Merta T, Mudry P, Polaskova K, Ivkovic TC, Adamcova S, Hornakova T, Jezova M, Kren L, Sterba J, Slaby O. Assessment of Tumor Mutational Burden in Pediatric Tumors by Real-Life Whole-Exome Sequencing and In Silico Simulation of Targeted Gene Panels: How the Choice of Method Could Affect the Clinical Decision? Cancers (Basel) 2020;12:E230. [PMID: 31963488 DOI: 10.3390/cancers12010230] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
2 White T, Szelinger S, LoBello J, King A, Aldrich J, Garinger N, Halbert M, Richholt RF, Mastrian SD, Babb C, Ozols AA, Goodman LJ, Basu GD, Royce T. Analytic validation and clinical utilization of the comprehensive genomic profiling test, GEM ExTra®. Oncotarget 2021;12:726-39. [PMID: 33889297 DOI: 10.18632/oncotarget.27945] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Lomberk G, Dusetti N, Iovanna J, Urrutia R. Emerging epigenomic landscapes of pancreatic cancer in the era of precision medicine. Nat Commun 2019;10:3875. [PMID: 31462645 DOI: 10.1038/s41467-019-11812-7] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 8.0] [Reference Citation Analysis]
4 McCord M, Steffens A, Javier R, Kam KL, McCortney K, Horbinski C. The efficacy of DNA mismatch repair enzyme immunohistochemistry as a screening test for hypermutated gliomas. Acta Neuropathol Commun 2020;8:15. [PMID: 32051040 DOI: 10.1186/s40478-020-0892-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 9.0] [Reference Citation Analysis]
5 Gutierrez ME, Price KS, Lanman RB, Nagy RJ, Shah I, Mathura S, Mulcahy M, Norden AD, Goldberg SL. Genomic Profiling for KRAS, NRAS, BRAF, Microsatellite Instability, and Mismatch Repair Deficiency Among Patients With Metastatic Colon Cancer. JCO Precis Oncol 2019;3:PO. [PMID: 32923867 DOI: 10.1200/PO.19.00274] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
6 Beaubier N, Bontrager M, Huether R, Igartua C, Lau D, Tell R, Bobe AM, Bush S, Chang AL, Hoskinson DC, Khan AA, Kudalkar E, Leibowitz BD, Lozachmeur A, Michuda J, Parsons J, Perera JF, Salahudeen A, Shah KP, Taxter T, Zhu W, White KP. Integrated genomic profiling expands clinical options for patients with cancer. Nat Biotechnol 2019;37:1351-60. [PMID: 31570899 DOI: 10.1038/s41587-019-0259-z] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 12.3] [Reference Citation Analysis]
7 Stenzinger A, Allen JD, Maas J, Stewart MD, Merino DM, Wempe MM, Dietel M. Tumor mutational burden standardization initiatives: Recommendations for consistent tumor mutational burden assessment in clinical samples to guide immunotherapy treatment decisions. Genes Chromosomes Cancer 2019;58:578-88. [PMID: 30664300 DOI: 10.1002/gcc.22733] [Cited by in Crossref: 72] [Cited by in F6Publishing: 73] [Article Influence: 24.0] [Reference Citation Analysis]
8 Chang H, Sasson A, Srinivasan S, Golhar R, Greenawalt DM, Geese WJ, Green G, Zerba K, Kirov S, Szustakowski J. Bioinformatic Methods and Bridging of Assay Results for Reliable Tumor Mutational Burden Assessment in Non-Small-Cell Lung Cancer. Mol Diagn Ther 2019;23:507-20. [PMID: 31250328 DOI: 10.1007/s40291-019-00408-y] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 9.5] [Reference Citation Analysis]
9 LeVee A, Lin CY, Posadas E, Figlin R, Bhowmick NA, Di Vizio D, Ellis L, Rosser CJ, Freeman MR, Theodorescu D, Freedland SJ, Gong J. Clinical Utility of Olaparib in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Review of Current Evidence and Patient Selection. Onco Targets Ther 2021;14:4819-32. [PMID: 34552338 DOI: 10.2147/OTT.S315170] [Reference Citation Analysis]
10 Choucair K, Morand S, Stanbery L, Edelman G, Dworkin L, Nemunaitis J. TMB: a promising immune-response biomarker, and potential spearhead in advancing targeted therapy trials. Cancer Gene Ther 2020;27:841-53. [PMID: 32341410 DOI: 10.1038/s41417-020-0174-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
11 Salgia R, Mambetsariev I, Pharaon R, Fricke J, Baroz AR, Hozo I, Chen C, Koczywas M, Massarelli E, Reckamp K, Djulbegovic B. Evaluation of Omics-Based Strategies for the Management of Advanced Lung Cancer. JCO Oncol Pract 2021;17:e257-65. [PMID: 32639928 DOI: 10.1200/OP.20.00117] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
12 Mambetsariev I, Pharaon R, Nam A, Knopf K, Djulbegovic B, Villaflor VM, Vokes EE, Salgia R. Heuristic value-based framework for lung cancer decision-making. Oncotarget 2018;9:29877-91. [PMID: 30042820 DOI: 10.18632/oncotarget.25643] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
13 Hill A, Gupta R, Zhao D, Vankina R, Amanam I, Salgia R. Targeted Therapies in Non-small-Cell Lung Cancer. Cancer Treat Res 2019;178:3-43. [PMID: 31209840 DOI: 10.1007/978-3-030-16391-4_1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
14 Rajurkar S, Mambetsariev I, Pharaon R, Leach B, Tan T, Kulkarni P, Salgia R. Non-Small Cell Lung Cancer from Genomics to Therapeutics: A Framework for Community Practice Integration to Arrive at Personalized Therapy Strategies. J Clin Med 2020;9:E1870. [PMID: 32549358 DOI: 10.3390/jcm9061870] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
15 Su D, Wu B, Shi L. Cost-Effectiveness of Genomic Test-Directed Olaparib for Metastatic Castration-Resistant Prostate Cancer. Front Pharmacol 2020;11:610601. [PMID: 33574757 DOI: 10.3389/fphar.2020.610601] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
16 Palmero R, Taus A, Viteri S, Majem M, Carcereny E, Garde-noguera J, Felip E, Nadal E, Malfettone A, Sampayo M, Riva F, Nagy RJ, Lanman RB, Faull I, Dix D, Karachaliou N, Rosell R. Biomarker Discovery and Outcomes for Comprehensive Cell-Free Circulating Tumor DNA Versus Standard-of-Care Tissue Testing in Advanced Non–Small-Cell Lung Cancer. JCO Precision Oncology 2021. [DOI: 10.1200/po.20.00241] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
17 Seoighe C, Bracken AP, Buckley P, Doran P, Green R, Healy S, Kavanagh D, Kenny E, Lawler M, Lowery M, Morris D, Morrissey D, O'Byrne JJ, Shields D, Smith O, Steward CA, Sweeney B, Kolch W. The future of genomics in Ireland - focus on genomics for health. HRB Open Res 2020;3:89. [PMID: 33855271 DOI: 10.12688/hrbopenres.13187.1] [Reference Citation Analysis]
18 Roberts JS, Gornick MC, Le LQ, Bartnik NJ, Zikmund-Fisher BJ, Chinnaiyan AM; MI-ONCOSEQ Study team. Next-generation sequencing in precision oncology: Patient understanding and expectations. Cancer Med 2019;8:227-37. [PMID: 30600607 DOI: 10.1002/cam4.1947] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 5.7] [Reference Citation Analysis]
19 Lee M, Eng G, Barbari SR, Deshpande V, Shcherbakova PV, Gala MK. Homologous Recombination Repair Truncations Predict Hypermutation in Microsatellite Stable Colorectal and Endometrial Tumors. Clin Transl Gastroenterol 2020;11:e00149. [PMID: 32352724 DOI: 10.14309/ctg.0000000000000149] [Reference Citation Analysis]
20 Meléndez B, Van Campenhout C, Rorive S, Remmelink M, Salmon I, D'Haene N. Methods of measurement for tumor mutational burden in tumor tissue. Transl Lung Cancer Res 2018;7:661-7. [PMID: 30505710 DOI: 10.21037/tlcr.2018.08.02] [Cited by in Crossref: 75] [Cited by in F6Publishing: 75] [Article Influence: 18.8] [Reference Citation Analysis]
21 Mambetsariev I, Wang Y, Chen C, Nadaf S, Pharaon R, Fricke J, Amanam I, Amini A, Bild A, Chu P, Erhunmwunsee L, Kim J, Munu J, Pillai R, Raz D, Sampath S, Vora L, Qiu F, Smith L, Batra SK, Massarelli E, Koczywas M, Reckamp K, Salgia R. Precision medicine and actionable alterations in lung cancer: A single institution experience. PLoS One 2020;15:e0228188. [PMID: 32045431 DOI: 10.1371/journal.pone.0228188] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
22 Cai B, Zhou ZY, Xue W, Hazra NC, Singh M, Mishra D, Brixner D, Oderda G, Biskupiak J. Budget impact of capmatinib for adults with metastatic non-small cell lung cancer harboring a MET exon 14 skipping mutation in the United States. J Med Econ 2021;24:131-9. [PMID: 33397178 DOI: 10.1080/13696998.2020.1867470] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Orellana TJ, Kim H, Beriwal S, Bhargava R, Berger J, Buckanovich RJ, Coffman LG, Courtney-Brooks M, Mahdi H, Olawaiye AB, Sukumvanich P, Taylor SE, Smith KJ, Lesnock JL. Cost-effectiveness analysis of tumor molecular classification in high-risk early-stage endometrial cancer. Gynecol Oncol 2021:S0090-8258(21)01515-8. [PMID: 34740462 DOI: 10.1016/j.ygyno.2021.10.071] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 van de Ven M, Simons MJHG, Koffijberg H, Joore MA, IJzerman MJ, Retèl VP, van Harten WH. Whole genome sequencing in oncology: using scenario drafting to explore future developments. BMC Cancer 2021;21:488. [PMID: 33933021 DOI: 10.1186/s12885-021-08214-8] [Reference Citation Analysis]
25 Roos A, Byron SA. Genomics-Enabled Precision Medicine for Cancer. Cancer Treat Res 2019;178:137-69. [PMID: 31209844 DOI: 10.1007/978-3-030-16391-4_5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]